Ichthammol (Ichthyol) Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is a standardised ammonium bituminosulfonate liquid derived from sulfonated shale oil. The product is assigned commercial model code ICH-VET-L and is supplied as a single pharmacopoeial liquid grade; no separate crystalline, polymorphic, or esterified forms are produced. The API is a dark brown to black, high-viscosity liquid with a characteristic bituminous odour and is fully miscible with water after reconstitution. In solid oral and premix applications, the liquid must be adsorbed onto a carrier such as microcrystalline cellulose, colloidal silicon dioxide, or maltodextrin before blending. The material is released only after verification of identity, purity, and microbial quality against current European Pharmacopoeia and United States Pharmacopeia general chapters applicable to veterinary raw materials.

Because ichthammol is a complex mixture rather than a single molecular entity, the pharmacopoeial monograph defines the acceptable source, sulfonation degree, neutralisation agent, and residual sulfur window. This distinguishes the veterinary API from industrial “ichthyol oil” and from technical-grade sulfonated shale oil used in drilling fluids or lubricants. Veterinary dosage form manufacturers use the API for non-sterile oral preparations, topical intermediates, and premixes; injectable applications require additional filtration validation and endotoxin control because the substance forms a colloidal dispersion rather than a true solution.

What Pharmacopoeial Specifications Define Veterinary-Grade Ichthammol?

Total sulfur content is the most critical assay parameter because it correlates with sulfonated shale oil concentration after correction for water and ash. The release limit of 10.0–14.0% w/w is typical for pharmacopoeial material; technical grades may fall outside this range due to incomplete neutralisation. The pH of a 10% aqueous dilution is controlled between 6.0–8.0, because alkaline degradation can release ammonia and acidic conditions can precipitate sulfonic acid fractions. Sulfated ash is limited to ≤1.0% to restrict inorganic contaminants, and heavy metals are limited to ≤40 ppm using Ph. Eur. 2.4.8 or USP <231>.

Analytical method transfer to a veterinary manufacturing site must include forced degradation data for thermal and oxidative stress. Because the API is chemically heterogeneous, solid dosage form development often uses chromatographic fingerprinting or total sulfur assay rather than a single-analyte active assay. The batch release document should include residual water content because water variation of ±5% w/w can shift the effective sulfur content per kilogram and alter tablet active load. The API is not sterile when received; terminal dosage forms may be preserved if non-sterile or sterilised by filtration if injectable. Residual organic solvents are not expected from the sulfonation process, but gas chromatographic screening is performed when the API is co-processed with ethanol or other volatile carriers.

Storage in 50 kg or 200 kg high-density polyethylene drums under nitrogen overlay is recommended. The product should be held at 2–30°C and protected from light. Below 2°C, the material thickens and may require drum heaters set at 40°C before transfer. Above 30°C, prolonged storage can increase ammonia loss and darken the oil; any off-gassing indicates that total sulfur and pH should be retested before release. Transfer lines of 316L stainless steel or polypropylene are preferred. Carbon steel and copper alloys are avoided because they can generate dark metal sulfides and raise heavy metal content. Open sampling under relative humidity above 60% should be controlled because the material is hygroscopic and water uptake can alter the mass balance of sulfur and water in a batch.

High-Shear Granulation and Low-Shear Blending Constraints for Oral Granules and Premixes

When a veterinary premix or granulated tablet intermediate is manufactured, liquid ichthammol is first diluted with 2–3 parts purified water and sprayed onto a pre-blend of microcrystalline cellulose and colloidal silicon dioxide in a bottom-drive high-shear granulator. Colloidal silicon dioxide at 5–15% w/w is commonly required to prevent reagglomeration of the liquid-loaded granule. A 50 L high-shear granulator with an impeller tip speed of 4–6 m/s and a chopper speed of 1500–3000 rpm produces granules with a target mean particle size of 150–400 µm. A wet massing time of 2–4 minutes after spray completion is common; prolonged wet massing above 8 minutes can generate overwetted agglomerates that dry into hard granules with poor tablet compactibility.

For dry blending of premixes without granulation, the liquid API is pre-adsorbed onto a carrier at a ratio of 1:4 to 1:9 API to carrier by weight before addition to a ribbon blender. Ribbon blender speed of 15–25 rpm and total blend time of 10–20 minutes are typical to distribute the adsorbed phase without oil droplet formation. Blend uniformity is verified by sulfur assay of 10 stratified samples; acceptance criteria require relative standard deviation below 5.0%. Premixes for medicated feed must meet the particle size and homogeneity requirements of EU Regulation 2019/4 or the equivalent regional veterinary premix standard applicable to the intended market.

Granule drying is a critical step because excessive heat can volatilise ammonia and change the reconstituted pH. Fluid-bed drying with an inlet air temperature of 50–70°C and exhaust temperature of 30–40°C is used; product temperature should not exceed 45°C. Final granule moisture is targeted at 1.5–3.0%. If granule moisture exceeds 3.0%, the material may adhere to feed frames on high-speed tablet presses. If moisture falls below 1.0%, electrostatic charging and segregation of the sulfonated carrier can occur. Milling through a 1.2 mm screen in a conical mill at 1000–1500 rpm is used to break oversize granules and narrow the particle size distribution.

Rotary tablet compression of ichthammol-loaded granules is performed on 27-station tools with precompression force of 20–30 kN and main compression force of 60–90 kN. Tablets are compressed to hardness 40–70 N and friability below 1.0% per Ph. Eur. 2.9.7 or USP <1216>. Disintegration is monitored by Ph. Eur. 2.9.1; for uncoated tablets, a target of ≤30 minutes in water at 37°C is typical. Capsule filling on a dosator-type machine requires the ichthammol-loaded powder to be plug-formable; poor plug hardness can produce weight variation exceeding ±5% for a 400 mg fill weight. Size 0 hard gelatin capsules usually require fill weights of 400–700 mg, while size 1 capsules are used when blend density exceeds 0.65 g/mL.

Uncoated tablets and hard gelatin capsules containing ichthammol require moisture-protective packaging. Stability studies under 40°C/75% RH for 6 months may show darkening of the tablet core and a small decrease in sulfur assay if packaging is inadequate. Capsules can be more sensitive because the hygroscopic API increases internal moisture and may promote shell cross-linking. Desiccant canisters with 1 g silica gel per 30 capsules are often included in high-density polyethylene bottles. Repeated exposure to ambient relative humidity above 60% can increase capsule brittleness and prolong disintegration. Antioxidant addition is not automatic; sulfur-containing API may interact with reducing agents, so forced-degradation studies are required before routine use in premixes or oral powders.

When Aqueous Ichthammol Solutions Are Processed Through Sterilising-Grade Filtration

When the intended dosage form is an injectable solution, the colloidal character of ichthammol imposes specific filtration and sterilisation constraints. A pre-filter train of polypropylene depth cartridges with retention ratings of 1.0 µm followed by 0.45 µm is used before a final 0.22 µm membrane. Hydrophilic polyethersulfone or polyvinylidene fluoride membranes are preferred because they show relatively low binding to sulfonated aromatic compounds; nylon membranes can produce assay loss through adsorption. The use of celite filter aids is not recommended because residual filter aid can raise sulfated ash and alter the release specification.

The solution pH prior to filtration should be 6.0–7.5. At pH below 5.0, precipitated sulfonic acid fragments can reduce filter throughput and cause visible haze after sterilisation. At pH above 9.0, free ammonia can accumulate in headspace and create container-closure incompatibility with elastomer stoppers. Buffer capacity is maintained with 10–50 mM citrate or phosphate; higher buffer strength is generally unnecessary and may increase injection site discomfort. Oral solutions and drench solutions are prepared at 5–20% w/w in purified water using a high-torque mixer with a propeller impeller at 300–600 rpm for 30–60 minutes. The liquid API is preheated to 40°C and added slowly to the vortex to avoid lumping. The final solution is passed through a 100–200 µm in-line screen to remove undispersed bituminous particles, and visible oil droplets must be absent after 24 h at room temperature.

Terminal autoclaving at 121°C for 15 minutes may be acceptable for veterinary injectable solutions only after confirming that the thermal cycle does not produce sediment, colour shift, or pH fall outside the registered specification. Sterilising filtration followed by aseptic filling is an alternative when heat exposure alters the colloidal state. Each production batch is tested for bacterial endotoxins using Ph. Eur. 2.6.14 or USP <85>; the limit is defined per species and route. Published pharmacokinetic data for systemic veterinary ichthammol is limited, so pilot safety studies in target species are required before injectable use can be registered.

Regulatory-Grade Ichthammol Is Not Chemically Equivalent to Technical Sulfonated Shale Oil or Coal Tar Fractions

The pharmacopoeial status of ichthammol is the principal differentiator from industrial sulfonated shale oil and coal tar derivatives. Technical-grade material is not manufactured under ICH Q7, does not carry a veterinary API batch certificate, and typically has higher heavy metal burden, uncontrolled moisture, and residual sulfonation acids. Coal tar fractions contain hydrophobic polycyclic aromatic hydrocarbons that are not water-miscible and may carry a different toxicological profile. Ichthammol is neutralised with ammonia to form ammonium bituminosulfonate, which gives water dispersibility and a buffered pH in aqueous systems. Sodium-neutralised shale oil alternatives are available but can contribute higher sodium load to oral and parenteral formulations, which is a relevant consideration in animals with sodium-restricted diets.

In veterinary topical products, ichthammol is often compared with zinc oxide, phenol, and neomycin sulfate. Zinc oxide provides astringent action but does not supply the sulfonated organic acid profile. Phenol has antimicrobial activity but is less colloidal and more tissue-irritating at equivalent concentrations. Neomycin sulfate is a single narrow-spectrum antibiotic, whereas ichthammol is a complex sulfonated mixture containing multiple organic sulfur compounds. These differences affect manufacturing: ichthammol solutions must be filtered to remove bituminous particulates, while simple antibiotic solutions may be clear and easier to sterilise. Conversely, ichthammol is more compatible with mildly alkaline pH than many antibiotic actives that require acidic pH stabilisation.

Process validation in a 600 L planetary mixer for a 250 kg premix batch has shown that adding ichthammol as a 20% aqueous dilution before final blending can reduce segregation compared with direct viscous-liquid addition. Direct addition of the liquid to a ribbon blender without pre-adsorption can produce oily agglomerates that do not pass a 1.0 mm sieve; these agglomerates may carry high sulfur content and cause non-uniformity. A validated adsorption step before blending is therefore considered mandatory for batch release under EU GMP Annex 2 or 21 CFR 210/211 where applicable.

Ichthammol is incompatible with strong oxidising agents, including hydrogen peroxide and potassium permanganate, because the sulfur-containing fractions can be oxidised. Contact with strong acids at pH below 5.0 should be avoided due to precipitation of sulfonic acid components. Formulations containing free ferric or ferrous ions should be avoided because dark iron-sulfonate complexes may form. Cationic surfactants can flocculate the colloidal solution unless compatibility is demonstrated. At relative humidity above 60%, open powder handling should be limited; loaded powders should be re-dried before compression if water content increases by more than 0.5% w/w. These restrictions apply to production-scale equipment and must be re-validated at each site because the material is not a uniform single molecule but a natural-derived complex mixture.